High-sensitivity CRP is correlated with neurologic symptoms and plaque instability in patients with severe stenosis of the carotid bifurcation

Vascular and Endovascular Surgery

Volumn 42, Issue 3, 2008, Pages 249-255

  Papas, Theophanis T ^a,d   Maltezos, Chrysostomos K ^a   Papanas, Nikolaos ^b   Kopadis, Georgios ^a   Marakis, Joseph ^a   Maltezos, Efstratios ^b   Bastounis, Elias ^c  

^a IASO GENERAL HOSPITAL   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d NONE   (Greece)

Author keywords

Atherosclerosis; Carotid; CRP; Inflammation; Vascular risk

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CAROTID ARTERY BIFURCATION; CAROTID ARTERY OBSTRUCTION; CLINICAL FEATURE; DIGITAL SUBTRACTION ANGIOGRAPHY; DISEASE ASSOCIATION; ECHOGRAPHY; ENDARTERECTOMY; FEMALE; HUMAN; INFLAMMATION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PROTEIN BLOOD LEVEL;

AGED; ANGIOGRAPHY, DIGITAL SUBTRACTION; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID STENOSIS; E-SELECTIN; ENDARTERECTOMY, CAROTID; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MACROPHAGES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; STROKE; ULTRASONOGRAPHY, DOPPLER, DUPLEX;

EID: 45449096905     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/1538574408314437     Document Type: Article

References (45)

1. Ingall T. Stroke-incidence, mortality, morbidity and risk. J Insur Med. 2004 ; 36: 143-152.
2. Deleu D., Hamad AA, Kamram S., El Siddig A., Al Hail H., Hamdy SM Ethnic variations in risk factor profile, pattern and recurrence of non-cardioembolic ischemic stroke. Arch Med Res. 2006 ; 37: 655-662.
3. Di Carlo A., Lamassa M., Baldereschi M., et al. Risk factors and outcome of subtypes of ischemic stroke. Data from a multicenter multinational hospital-based registry. The European Community Stroke Project. J Neurol Sci. 2006 ; 244: 143-150.
4. Juttler E., Kohrmann M., Schellinger PD Therapy for early reperfusion after stroke. Nat Clin Pract Cardiovasc Med. 2006 ; 3: 656-663.
5. Bertges DJ, Muluk V., Whittle J., Kelley M., MacPherson DS, Muluk SC Relevance of carotid stenosis progression as a predictor of ischemic neurological outcomes. Arch Intern Med. 2003 ; 163: 2285-2289.
6. Blaser T., Hofmann K., Buerger T., Effenberger O., Wallesch CW, Goertler M. Risk of stroke, transient ischemic attack, and vessel occlusion before endarterectomy in patients with symptomatic severe carotid stenosis. Stroke. 2002 ; 33: 1057-1062.
7. Mackinnon AD, Jerrard-Dunne P., Sitzer M., Buehler A., von Kegler S., Markus HS Rates and determinants of site-specific progression of carotid artery intima-media thickness: the carotid atherosclerosis progression study. Stroke. 2004 ; 35: 2150-2154.
8. Mayo SW, Eldrup-Jorgensen J., Lucas FL, Wennberg DE, Bredenberg CE Carotid endarterectomy after NASCET and ACAS: a statewide study. North American Symptomatic Carotid Endarterectomy Trial. Asymptomatic Carotid Artery Stenosis Study. J Vasc Surg. 1998 ; 27: 1017-1022.
9. Sullivan HG, Cogbill TH, Fischer GG, Hoppe CM, Lambert PJ, Mathiason MA An institutional approach to maintenance of excellent outcomes for carotid endarterectomy in a setting with moderate-to-low procedure volume. J Am Coll Surg. 2006 ; 203: 634-641.
10. Mansour MA, Littooy FN, Watson WC, et al. Outcome of moderate carotid artery stenosis in patients who are asymptomatic. J Vasc Surg. 1999 ; 29: 217-225.
11. Rockman CB, Riles TS, Lamparello PJ, et al. Natural history and management of the asymptomatic, moderately stenotic internal carotid artery. J Vasc Surg. 1997 ; 25: 423-431.
12. Brott T., Toole JF Medical compared with surgical treatment of asymptomatic carotid artery stenosis. Ann Intern Med. 1995 ; 123: 720-722.
13. Barnett HJ, Meldrum HE, Eliasziw M. The dilemma of surgical treatment for patients with asymptomatic carotid disease. Ann Intern Med. 1995 ; 123: 723-725.
14. Hankey GJ Asymptomatic carotid stenosis: how should it be managed ? Med J Aust. 1995 ; 163: 197-200.
15. Raman KG, Layne S., Makaroun MS, et al. Disease progression in contralateral carotid artery is common after endarterectomy. J Vasc Surg. 2004 ; 39: 52-7.
16. Pepys MB, Hirschfield GM C-reactive protein: a critical update. J Clin Invest. 2003 ; 111: 1805-1812.
17. Doggen CJM, Berckmans RJ, Sturk A., Manger V., Rosendaal FR C-reactive protein, cardiovascular risk factors and the association with myocardial infarction in men. J Intern Med. 2000 ; 248: 406-414.
18. Toss H., Lindhal B., Siegbahn A., Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation. 1997 ; 96: 4204-4210.
19. Musicant SE, Taylor LM Jr, Peters D., et al. Prospective evaluation of the relationship between C-reactive protein, D-dimer and progression of peripheral arterial disease. J Vasc Surg. 2006 ; 43: 772-780.
20. Ridker PM, Cushman M., Stampfer MJ, Tracy RP, Hennekens CH Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998 ; 97: 425-428.
21. Di Napoli M., Papa F., Bacola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke. 2001 ; 32: 133-138.
22. Muir KW, Weir CJ, Alwan W., Squire IB, Lees KR C-reactive protein and outcome after ischemic stroke. Stroke. 1999 ; 30: 981-985.
23. Makita S., Nakamura M., Hiramori K. The association of C-reactive protein levels with carotid intima-media complex thickness and plaque formation in the general population. Stroke. 2005 ; 36: 2138-2142.
24. Bassuk SS, Rifai N., Ridker PM High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol. 2004 ; 29: 439-493.
25. Tsimikas S., Willerson JT, Ridker PM C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol. 2006 ; 47 (suppl 8). C19 - C31.
26. Yeh ET High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease. Clin Cardiol. 2005 ; 28: 408-412.
27. Okulla T., Gass S., Bohme K., et al. Circulating adhesion molecules in patients with internal carotid artery stenosis. Cerebrovasc Dis. 2002 ; 14: 9-14.
28. Rerkasem K., Shearman CP, Williams JA, et al. C-reactive protein is elevated in symptomatic compared with asymptomatic patients with carotid artery disease. Eur J Vasc Endovasc Surg. 2002 ; 23: 505-509.
29. Moneta GL, Edwards JM, Chitwood RW, et al. Correlation of North American Symptomatic Carotid Endarterectomy Trial (NASCET) angiographic definition of 70% to 99% internal carotid artery stenosis with duplex scanning. J Vasc Surg. 1993 ; 17: 152-157.
30. De Bray JM, Glatt B. Quantification of atheromatous stenosis in the extracranial internal carotid artery. Cerebrovasc Dis. 1995 ; 5: 414-426.
31. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA. 1995 ; 73: 1421-1428.
32. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991 ; 325: 445-453.
33. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Atherosclerosis, American Heart Association. Circulation. 1995 ; 92: 1355-1374.
34. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997 ; 20: 1183-1197.
35. Joint National Committee. The seventh report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC 7). JAMA. 2003 ; 289: 2560-2572.
36. National Cholesterol Education Program (NCEP). Detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation. 2002 ; 24: 3145-3421.
37. Rose GA, Blackburn H. Cardiovascular Survey Methods. WHO Monograph Series No 56. Geneva, Switzerland: World Health Organization ; 1968.
38. Hiatt WR Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001 ; 344: 1608-1621.
39. Alvarez Garcia B., Ruiz C., Chacon P., Sabin JA, Matas M. High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque. J Vasc Surg. 2003 ; 38: 1018-1024.
40. Papanas N., Tziakas D., Chalikias G., et al. Gliclazide treatment lowers serum ICAM-1 levels in poorly controlled type 2 diabetic patients. Diabetes Metab. 2006 ; 32: 344-349.
41. Magyar MT, Szikszai Z., Balla J., et al. Early-onset carotid atherosclerosis is associated with increased intima-media thickness and elevated serum levels of inflammatory markers. Stroke. 2003 ; 34: 58-63.
42. Wang TJ, Nam BH, Wilson PW, et al. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2002 ; 22: 1662-1667.
43. Leinonen ES, Hiukka A., Hurt-Camejo E., et al. Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes. J Intern Med. 2004 ; 256: 119-127.
44. Testa A., Benedetto FA, Spoto B., et al. The E-selectin gene polymorphism and carotid atherosclerosis in end-stage renal disease. Nephrol Dial Transplant. 2006 ; 21: 1921-1926.
45. Tziakas DN, Lazarides MK, Tentes IK, et al. Gelatinases [matrix metalloproteinase-2 (MMP-2) and MMP-9] induce carotid plaque instability but their systemic levels are not predictive of local events. Ann Vasc Surg. 2005 ; 19: 529-533.